Ann: TGA Registration Update, page-137

First 137 Last

Share
Profile

Follow
Charles89

4,995 Posts.

2157

15/12/21

12:46

Post #: 58308059
Share

Originally posted by griff98: ↑

If a big part of your reason to own ADO shares is because of the EuGeni roll-out, one question you should ask yourself (something I asked myself whilst looking at the mirror) is how long do you think Covid testing will be required. If you feel that within a few months it won't be needed then perhaps you should take capital out and put somewhere else (there's a lot of exciting opportunities out there). However, if you believe testing will play a critical roll in 12+ months then something like this shouldn't be too much of a concern (my current feeling toward the situation). This is just TGA doing its due diligence. We've got the science and we're getting the right people into the right positions. Remove yourself from the present and picture yourself a few years down the road. The long hard days awaiting TGA approval will be a drop in the ocean in the scheme of things (IMO, DYOR, so on and so forth). Diamond hands are needed to hold these shares but you won't be getting any of mine.

Expand

Interestingly, " how long do you think Covid testing will be required", is only part of the question.

As you said, investment based on EuGeni roll-out, but in the short/medium term, EuGeni will have a suite of different tests that is not just Covid-19 related, therefore, IMO the longer term or the more sustainable question should be:

How many other addressable conditions/virus/market can EuGeni serve?

EuGeni's RAT is just one of many.

ADO Price at posting: 17.3¢ Sentiment: Buy Disclosure: Held
26 Upvote

0 Great analysis

Reply

Top Stories

AZY

Antipa highlights 33% increase in contained gold at Minyari Dome

AI leader NVIDIA has shaken off the latest scare once again. Can it keep rising?

Pacific Smiles receives new takeover offer, boosting valuation of shares by 50 cents each

CHN

Chalice's Gonneville noted as 'strategic project' by WA but nickel prices still too low

BUB

Bubs Australia forecasts full US FDA market access approval by October 2025

There are more pages in this discussion • 2,281 more messages in this thread...

First 137 Last

Add ADO (ASX) to my watchlist

(20min delay)
Last 2.3¢		Change 0.000(0.00%)		Mkt cap ! $57.26M

Open	High	Low	Value	Volume
2.3¢	2.3¢	2.3¢	$268	11.65K

Buyers (Bids)

No.	Vol.	Price($)
5	1193555	2.1¢

Sellers (Offers)

Price($)	Vol.	No.
2.3¢	1243793	6

View Market Depth

No.	Vol.	Price($)
5	1193555	0.021
11	1241001	0.020
6	1027236	0.019
6	2172779	0.018
2	64748	0.017

Price($)	Vol.	No.
0.023	1243793	6
0.024	716664	6
0.025	1050470	10
0.026	291415	3
0.027	250000	1

Last trade - 10.02am 17/09/2024 (20 minute delay)

ADO (ASX) Chart

Ann: TGA Registration Update, page-137

Antipa highlights 33% increase in contained gold at Minyari Dome

AI leader NVIDIA has shaken off the latest scare once again. Can it keep rising?

Pacific Smiles receives new takeover offer, boosting valuation of shares by 50 cents each

Chalice's Gonneville noted as 'strategic project' by WA but nickel prices still too low

Bubs Australia forecasts full US FDA market access approval by October 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: TGA Registration Update, page-137

Top Stories

Antipa highlights 33% increase in contained gold at Minyari Dome

AI leader NVIDIA has shaken off the latest scare once again. Can it keep rising?

Pacific Smiles receives new takeover offer, boosting valuation of shares by 50 cents each

Chalice's Gonneville noted as 'strategic project' by WA but nickel prices still too low

Bubs Australia forecasts full US FDA market access approval by October 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News